Abbott Labs Files 8-K on Financials

TL;DR

Abbott Labs dropped an 8-K on Jan 22 detailing financial results. Check it out.

AI Summary

Abbott Laboratories filed an 8-K on January 22, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 100 Abbott Park Road, Abbott Park, Illinois.

Why It Matters

This filing provides an update on Abbott Laboratories' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

• ABBOTT LABORATORIES (company) — Registrant
• 100 Abbott Park Road (location) — Principal executive offices address
• Abbott Park (location) — City of principal executive offices
• Illinois (location) — State of incorporation and principal executive offices
• January 22, 2025 (date) — Date of report

FAQ

Filing Documents

• abt-20250122.htm (8-K) — 28KB
• abt-2024q4xexhibitx991.htm (EX-99.1) — 843KB
• abbottlogo.jpg (GRAPHIC) — 7KB
• 0001628280-25-002092.txt ( ) — 1078KB
• abt-20250122.xsd (EX-101.SCH) — 2KB
• abt-20250122_def.xml (EX-101.DEF) — 15KB
• abt-20250122_lab.xml (EX-101.LAB) — 26KB
• abt-20250122_pre.xml (EX-101.PRE) — 16KB
• abt-20250122_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 22, 2025, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2024. Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, a non-cash valuation allowance adjustment, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit No. Exhibit 99.1 Press Release dated January 22, 2025 (furnished pursuant to Item 2.02). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBOTT LABORATORIES Date: January 22, 2025 By: /s/ Philip P. Boudreau Philip P. Boudreau Executive Vice President, Finance and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR